Holmium-166 Retrospective Collection of Real-World Data
The primary objective of the study is to further describe the general safety and clinical performance of QuiremSpheresTM Holmium-166 Microspheres and QuiremScoutTM Holmium-166 Microspheres in a real-world post-market setting, with specific attention to outcomes per tumor origin.
Indication: Hepatocellular Carcinoma
Modality: RNA therapy
Target: Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres
Sponsor: Terumo Europe N.V.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres
View original source fields
Condition raw: Hepatocellular Carcinoma, Metastatic Cancer
Condition normalized: Hepatocellular Carcinoma, Metastatic Cancer
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres
Target normalized: Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres